For example, the guideline suggests a baseline HbA1c and a plasma glucose check before commencing anti‐cancer therapy or steroids, monitoring of random plasma glucose at each treatment visit, patient education, and collaborating with the diabetes team, for example, for support in titrating insulin.64 This evidence concerns the gene INS and diabetes mellitus.